Table 1 Clinicopathological characteristics of 420 patients with early-stage breast cancer treated with anti-HER2-targeted therapy.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Characteristic | No. (%) | Characteristic | No. (%) |
|---|---|---|---|
Age, years | N stage | ||
< 60 | 325 (77.4) | N0-1 | 165 (39.3) |
≥ 60 | 95 (22.6) | N2-3 | 255 (60.7) |
BMI (kg/m2) | Tumor stage | ||
< 24 | 197 (46.9) | I | 50 (11.9) |
≥ 24 | 223 (53.1) | II | 291 (69.2) |
Menopausal status | III | 79 (18.8) | |
Premenopause | 192 (45.7) | HR status | |
Postmenopausal | 228 (54.3) | Positive | 341 (81.2) |
Hypertension | Negative | 79 (18.8) | |
Yes | 98 (23.3) | Ki67 | |
No | 322 (76.7) | < 20% | 59 (14.0) |
Diabetes | ≥ 20% | 361 (86.0) | |
Yes | 52 (12.4) | Neoadjuvant therapy | |
No | 368 (87.6) | Yes | 113 (26.9) |
CAD | No | 307 (73.1) | |
Yes | 66 (15.7) | Surgery type | |
No | 354 (84.3) | Breast conserving | 48 (11.4) |
Smoking | Mastectomy | 372 (88.6) | |
Yes | 38 (9.0) | Anthracyclines | |
No | 382 (91.0) | Yes | 294 (70.0) |
Invasive ductal carcinoma | No | 126 (30.0) | |
Yes | 399 (95) | Targeted therapy | |
No | 21 (5) | H | 230 (54.8) |
Histilogical grade | HP | 190 (45.2) | |
I | 37 (8.8) | Radiotherapy | |
II | 302 (71.9) | Yes | 360 (85.7) |
III | 81 (19.3) | No | 60 (14.3) |
T stage | Radiotherapy position | ||
T1–2 | 318 (75.7) | Left chest wall area | 186 (51.7) |
T3–4 | 102 (24.3) | Right chest wall area | 174 (48.3) |
